Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
phenylephrine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | phenylephrine |
| Name | Type | Description |
|---|---|---|
| phenylephrine HCl | DRUG | A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule |
Inclusion Criteria: * Male and female children and adolescents, ages 2 to \< 18 years, with a minimum weight of 24 pounds will be eligible to participate. In addition, each subject will be \> 5th percentile and \< 95th percentile for weight based on age and gender. * Subjects will have a body mass ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
Phenylephrine is used for rhinitis, a condition involving inflammation of the nasal passages. It is being studied as a small molecule treatment in the respiratory therapeutic area. The drug is currently in Phase 1 clinical development and is being investigated for its effects in patients with rhinitis.
Phenylephrine is a small molecule that acts as a decongestant. It works by constricting blood vessels in the nasal passages, which reduces swelling and congestion associated with rhinitis. This mechanism helps to relieve nasal symptoms by decreasing blood flow to the inflamed tissues.
Phenylephrine is being developed by Johnson & Johnson, a multinational pharmaceutical company. The company is listed on the stock exchange under the ticker symbol JNJ. Johnson & Johnson is conducting clinical research to evaluate the safety and efficacy of phenylephrine for the treatment of rhinitis.
Phenylephrine is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 1 trial is focused on evaluating the drug's pharmacokinetics, which involves studying how the drug is absorbed, distributed, metabolized, and excreted in the body.
Phenylephrine has been studied in a Phase 1 clinical trial with the identifier NCT00762567, titled 'Phenylephrine Pediatric Pharmacokinetic Study'. This trial was conducted in the United States and enrolled 36 participants with rhinitis. The study has been completed and was not randomized or double-blinded.
Phenylephrine is a decongestant that works by narrowing blood vessels in the nasal passages to reduce swelling and congestion. It is similar to other decongestants like pseudoephedrine, but it has a different chemical structure and mechanism of action. Phenylephrine is commonly used in over-the-counter cold and allergy medications.